SecBot SecBot
15-12G ·Filed Jul 23, 2026

ESPR

Esperion Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed3mo ago SEC0001104659-26-086097
Deregistration
Actionable Insight • Neutral

The deregistration is the final step in the going-private transaction. No further public trading or SEC filings are expected. Shareholders who tendered shares in the merger have already received the $3.16 per share plus CVR consideration. Monitor for any post-merger CVR events or appraisal rights deadlines.

DirectionNeutral
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

Executive Summary

Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effective immediately. This is the final procedural step following the company's delisting from Nasdaq on July 13, 2026, after its acquisition by ArchiMed (via Essence Parent Inc.). With only 1 holder of record, the company will cease all SEC reporting obligations, completing its transition to a private entity.

Key Facts

  • Form 15-12G filed to terminate registration under Section 12(g) of the Securities Exchange Act of 1934.
  • Approximate number of holders of record as of the certification date: 1.
  • Filing follows a 25-NSE delisting from Nasdaq on July 13, 2026, related to the acquisition by ArchiMed.
  • The company will no longer file periodic reports with the SEC (Forms 10-K, 10-Q, 8-K, etc.).

Financial Impact

No financial figures provided in the filing. The deregistration is a procedural step after the completed acquisition; the company is now private.

Risk Factors

  • No ongoing public disclosure or SEC oversight for the company.
  • Minority shareholders who did not tender may face illiquidity and limited information rights.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
15-12G Filing (Primary)0001104659-26-086097
Document: 0001104659-26-086097-index-headers.html0001104659-26-086097
Document: 0001104659-26-086097-index.html0001104659-26-086097
Document: 0001104659-26-086097.txt0001104659-26-086097

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 Viewing No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026